SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-256763
Filing Date
2022-10-03
Accepted
2022-10-03 17:06:48
Documents
13
Period of Report
2022-09-30
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d341793d8k.htm   iXBRL 8-K 25512
2 EX-3.2 d341793dex32.htm EX-3.2 460370
  Complete submission text file 0001193125-22-256763.txt   675444

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rprx-20220930.xsd EX-101.SCH 2863
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rprx-20220930_lab.xml EX-101.LAB 17981
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rprx-20220930_pre.xml EX-101.PRE 11263
7 EXTRACTED XBRL INSTANCE DOCUMENT d341793d8k_htm.xml XML 3662
Mailing Address 110 EAST 59TH STREET NEW YORK NY 10022
Business Address 110 EAST 59TH STREET NEW YORK NY 10022 (212) 883-0200
Royalty Pharma plc (Filer) CIK: 0001802768 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39329 | Film No.: 221288340
SIC: 2834 Pharmaceutical Preparations